BOLDER BIOTECHNOLOGY INC
- LOUISVILLE, CO 80027-3109
- bolderbio.com (company website, opens in a new tab)
- Corporate Entity (Not Tax Exempt)
- SAM active
- No verified credentials yet
- CMMCNot on file
- SPRSNone
- FCLVisible to paid members
- Small Business
Registration and small-business types: SAM.gov, synced Nov 9, 2026. Compliance: self-attested by the company unless marked verified. The SPRS chip shows a range, never the exact score. How verification works
- 36-mo obligations
- $0
- Awards on record
- 1
- Contract vehicles
- 0
- Verified credentials
- 0
Compliance posture: unverified (SAM.gov baseline only)
BOLDER BIOTECHNOLOGY INC has not claimed this profile. What you see comes from public SAM.gov and USAspending records; no one from the company has confirmed CMMC, SPRS or clearance details yet. Learn more about CMMC 2.0
About BOLDER BIOTECHNOLOGY INC
- Headquarters
- LOUISVILLE, CO 80027-3109
Identifiers
UEI and CAGE come from SAM.gov. Other identifiers are listed by the company.
- UEICJ6GFX2TU3J4
- CAGE1PUB8
Capabilities & differentiators
No capability narrative yet
Compliance posture
No compliance posture published yet
Facility clearance
Facility clearance: visible to paid members
Clearance levels are shown only to paying members; TeamingIndex does not advertise clearances (NISPOM 32 CFR 117.9). Learn more about facility clearances · Compare plans
Past performance
- 36-month obligations
- $0
- Awards on record
- 1
- Top funding agencies
- n/a
Awards
75N93023C00011
Completed: Period of performance ended Jun 30, 2026ADVANCED DEVELOPMENT OF BBT-059 AS A RADIATION MEDICAL COUNTERMEASURE FOR DOSING UP TO 48H POST EXPOSURE"
Department of Health and Human Services · National Institutes of Health
- Obligated
- $3.1M
- Period of performance
- Jul 1, 2023 – Jun 30, 2026
| Award | Agency | NAICS · PSC | Obligated | Period of performance | Recompete |
|---|---|---|---|---|---|
75N93023C00011 ADVANCED DEVELOPMENT OF BBT-059 AS A RADIATION MEDICAL COUNTERMEASURE FOR DOSING UP TO 48H POST EXPOSURE" | Department of Health and Human Services · National Institutes of Health | 541714 · AN12HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH | $3.1M | Jul 1, 2023 – Jun 30, 2026 | Completed: Period of performance ended Jun 30, 2026 |
Contract vehicles
No contract vehicles on file
Proven teaming graph
No sub-award reports yet
Source: USAspending.gov sub-award reports (FSRS) (opens in a new tab) · sync date not recorded · Prime contractors report first-tier subcontracts of $30,000 or more. Amounts are reported sub-award values.
SBIR/STTR portfolio
SBIR/STTR awardee — Phase III-eligible for work derived from its SBIR/STTR projects
Agencies may award follow-on Phase III work without a new competition when it builds on this company’s earlier SBIR/STTR projects. Other work is competed as usual.
- Awards on record
- 52 awards
- Total awarded
- $22,870,169
- By phase
- SBIR Phase I: 34
- SBIR Phase II: 18
- By agency
- Department of Health and Human Services: 51
- Department of Defense: 1
- Active projects
- 0 projects
- Projects whose contract end date is today or later.
- Phase II ending within 12 months
- 0 projects
- Phase II projects ending within 12 months. Agencies may award Phase III work without a new competition only when it derives from, extends or completes these projects.
- By year
- 2024: 1
- 2023: 1
- 2021: 2
- 2019: 1
- 2013: 1
- 2010: 1
- 2009: 3
- 2008: 2
- 2007: 2
- 2006: 1
- 2005: 3
- 2004: 6
- 2003: 2
- 2002: 4
- 2001: 5
- 2000: 10
- 1999: 3
- 1998: 3
- 1997: 1
Awards (most recent first)
Improving survival from Burkholderia pseudomallei and other pathogenic intracellular bacteria
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2024 · $295,924
Feb 1, 2024 – Jan 31, 2025
Solicitation PA22-176 (2022) · Topic NIAID
Novel drug combinations for improving survival from acute radiation syndrome when administered 48 hours post- irradiation
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2023 · $1,717,432
May 23, 2023 – Apr 30, 2025
Solicitation PA21-259 (2021) · Topic NIAID
Evaluating BBT-059 as a medical countermeasure to protect against hematopoietic acute radiation syndrome
SBIR Phase I · Department of Defense (Defense Health Agency) · 2021 · $249,877
Aug 23, 2021 – Mar 22, 2022
Solicitation 21.1 (2021) · Topic DHA211-007
Stimulating innate immunity to protect against Ebola virus infection
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2021 · $300,000
Jul 2, 2021 – Jun 30, 2022
Solicitation PA20-260 (2020) · Topic NIAID
Novel drugs combinations for improving survival from Acute Radiation Syndrome when administered 48h postirradiation
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2019 · $593,507
Jul 12, 2019 – Jun 30, 2021
Solicitation PA18-525 (2018) · Topic R
Long-Acting G-CSF Analog for Treating ARS
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2013 · $3,196,000
Mar 8, 2013 – Feb 29, 2016
Solicitation PA12-044 (2015) · Topic NIAID
Long-Acting IL-11 Analog for Treating Acute Radiation Syndrome
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2010 · $600,000
Solicitation PHS2010-2 (2010) · Topic NIAID
Long-Acting G-CSF analogs for treating acute radiation syndrome
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2009 · $599,885
Solicitation PHS2009-2 (2009)
GM-CSF analogs for treating acute radiation syndrome
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2009 · $599,901
Solicitation PHS2009-2 (2009)
Long-acting EPO analog for treating anemia associated with chronic kidney disease
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2009 · $1,240,490
Solicitation PHS2009-2 (2009)
Long-acting Growth Hormone for Treating HIV-Associated Adipose Redistribution Syn
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2008 · $1,976,500
Solicitation PHS2007-2 (2008)
Long Acting Beta Interferon for Treating Multiple Sclerosis - Phase II Continuing
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2008 · $1,617,340
Solicitation PHS2007-2 (2008)
Long Acting IFN-gamma for Treating Immunodeficiencies
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2007 · $363,565
Solicitation year 2007
Long Acting VEGF Binding Proteins for Treating Rheumatoid Arthritis
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2007 · $338,923
Solicitation year 2007
Long Acting VEGF BInding Proteins for Treating Cancer
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2006 · $775,847
Solicitation PHS2006-2 (2006)
Long-Acting IFN-gamma for Treating Immunodeficiencies
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2005 · $99,000
Solicitation PHS2005-2 (2005)
Long-Acting IFN-gamma for Treating Ovarian Cancer
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2005 · $121,844
Solicitation PHS2005-2 (2005)
PEGylated Butyrylcholinesterase used as a Bioscavenger
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2005 · $121,844
Solicitation PHS2005-2 (2005)
Long-Acting Growth Hormone For HIV-Associated Wasting
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2004 · $303,204
Solicitation PHS2004-2 (2004)
Long Acting VEGF Inhibitor for Treating RA
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2004 · $100,000
Solicitation PHS2004-2 (2004)
Long-Acting VEGF Binding Proteins for Treating Cancer
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2004 · $100,000
Solicitation PHS2004-2 (2004)
Long Acting EPO For Treating Chronic Kidney Disease
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2004 · $500,000
Solicitation PHS2004-2 (2004)
Long-Acting Endostatin for Treating Cancer
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2004 · $819,961
Solicitation PHS2004-2 (2004)
Long-Acting Beta Interferon for Multiple Scierosis
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2004 · $749,898
Solicitation PHS2004-2 (2004)
Long-Acting IL-11 for Treating Thrombocytopenia
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2003 · $0
Showing the 25 most recent of 52 awards.
Source: SBIR.gov award data file (opens in a new tab) · as of Nov 12, 2026 · file published Nov 1, 2026
FedRAMP offerings
No FedRAMP Marketplace listing
Source: FedRAMP Marketplace (opens in a new tab) · sync date not recorded
Exclusions & screening
SAM.gov exclusions
Not yet checked against SAM.gov exclusions.
Agencies generally may not award to excluded parties, and primes may not subcontract with them above the threshold in FAR 52.209-6 (except COTS items) without a compelling reason reported to the contracting officer (FAR 9.405, 9.405-2). Some exclusion types apply only to specific programs: read the record on SAM.gov.
Source: SAM.gov Exclusions (opens in a new tab) · sync date not recorded
Consolidated Screening List
No confirmed match on the Consolidated Screening List (screened Nov 13, 2026).
The list combines Commerce, State and Treasury export-control and sanctions lists. A “no match” result is a name-and-address screen, not an export-compliance determination.
Source: ITA Consolidated Screening List (opens in a new tab) · as of Nov 13, 2026
GSA CALC+ rate benchmark
No GSA CALC+ rates on record
Source: GSA CALC+ awarded ceiling rates (opens in a new tab) · sync date not recorded
NAICS, PSC & socio-economic status
NAICS codes
- 541714Research and Development in Biotechnology (except Nanobiotechnology)PrimarySmall business under this code’s size standard
- 541715Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
SAM.gov reports this entity as small under 1 of 2 NAICS codes. Size is determined per code (SBA size standards).
Product & service codes (PSC)
- AJ11GENERAL SCIENCE AND TECHNOLOGY R&D SERVICES; GENERAL SCIENCE AND TECHNOLOGY; BASIC RESEARCH
- AJ12GENERAL SCIENCE AND TECHNOLOGY R&D SERVICES; GENERAL SCIENCE AND TECHNOLOGY; APPLIED RESEARCH
- AJ13GENERAL SCIENCE & TECHNOLOGY R&D SVCS; GENERAL SCIENCE & TECHNOLOGY; EXPERIMENTAL DEVELOPMENT
PSC names from the Acquisition.gov PSC Manual (opens in a new tab) (April 2025 edition), checked Nov 12, 2026.
Teaming preferences
This company has not published teaming preferences.
Business development contact
No BD contact published
Corporate hierarchy
No parent entity reported in SAM.gov.
SBA counts affiliates when it determines whether a business is small (13 CFR 121.103), so a parent’s size can matter for set-aside work.
Data sources & provenance
SAM.gov
Registration, CAGE, NAICS, socio-economic status, corporate hierarchy and exclusions. Last synced Nov 9, 2026.
USAspending.gov
Prime award history and obligations (FPDS), synced nightly.
The contractor
Nothing yet: this profile has not been claimed by the company.
TeamingIndex verification
Credentials marked Verified were checked by a TeamingIndex reviewer; everything else is self-attested.
Corrections
Corrections to SAM.gov data must be made in SAM.gov; TeamingIndex picks them up on the next nightly sync. Go to SAM.gov (opens in a new tab)
Machine-readable: capability.md schema.org JSON-LD embedded in this page.
Zero CUI: TeamingIndex stores verification metadata only, never System Security Plans, POA&Ms or DD Form 254s.
Teaming
Ready to team with BOLDER BIOTECHNOLOGY INC?
Send an introduction and propose a mutual NDA. Their team is notified right away, and you can share the capability statement with your capture team.